^
Association details:
| Biomarker: | PIK3CA mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer
Excerpt:
...we have investigated PIK3CA, EGFR, and KRAS gene mutations in patients with advanced NSCLC who had been treated with gefitinib or erlotinib...Median TTP was significantly shorter in the patients with mutated PIK3CA and KRAS (log-rank test, p = 0.01, and p = 0.003...PIK3CA and KRAS mutations seem to be indicators of resistance and poor survival in patients with NSCLC treated with EGFR-TKIs.
DOI:
10.1097/JTO.0b013e31820a3a6b
